Cargando…

Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: a systematic review and meta-analysis

BACKGROUND: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are almost always treated with glucocorticoids (GCs), but long-term GC use is associated with diabetes mellitus (DM). The absolute incidence of this complication in this patient group remains unclear. OBJECTIVE: To quantify the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Lana Yin Hui, Harris, Emma, West, Robert M, Mackie, Sarah Louise
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Vasculitis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845432/ https://www.ncbi.nlm.nih.gov/pubmed/29531778 http://dx.doi.org/10.1136/rmdopen-2017-000521

Ejemplares similares

Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort
por: Esen, Idil, et al.
Publicado: (2023)

Association between infection and the onset of giant cell arteritis and polymyalgia rheumatica: a systematic review and meta-analysis
por: Pacoureau, Lucas, et al.
Publicado: (2023)

Humoral and cellular SARS-CoV-2 vaccine responses in patients with giant cell arteritis and polymyalgia rheumatica
por: van Sleen, Yannick, et al.
Publicado: (2022)

Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review
por: Mackie, Sarah Louise, et al.
Publicado: (2015)

Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases
por: Izumi, Keisuke, et al.
Publicado: (2015)

Balancing on the edge: implications of a UK national audit of the use of BSR-BHPR guidelines for the diagnosis and management of polymyalgia rheumatica
por: Das, Parthajit, et al.
Publicado: (2015)

Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study
por: Cutolo, Maurizio, et al.
Publicado: (2017)

Rapid glucocorticoid tapering regimen in patients with giant cell arteritis: a single centre cohort study
por: Mensch, Noemi, et al.
Publicado: (2023)

Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab
por: Stone, John H., et al.
Publicado: (2019)

Is Tocilizumab Effective and Safe in Polymyalgia Rheumatica and Giant-Cell Arteritis With Polymyalgia Rheumatica?
por: Farinango, Michelle, et al.
Publicado: (2022)

Treatment failure in giant cell arteritis
por: Unizony, Sebastian H, et al.
Publicado: (2021)

Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids
por: Estupiñán-Moreno, Elkyn, et al.
Publicado: (2022)

Distribution patterns of arterial affection and the influence of glucocorticoids on (18)F-fluorodeoxyglucose positron emission tomography/CT in patients with giant cell arteritis
por: Malich, Leander, et al.
Publicado: (2022)

Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis
por: Emamifar, Amir, et al.
Publicado: (2021)

Performance of the 2022 ACR/EULAR giant cell arteritis classification criteria for diagnosis in patients with suspected giant cell arteritis in routine clinical care
por: Molina-Collada, Juan, et al.
Publicado: (2023)

Need and value of targeted immunosuppressive therapy in giant cell arteritis
por: Sandovici, Maria, et al.
Publicado: (2022)

Validity of the EULAR recommendations on the use of ultrasound in the diagnosis of giant cell arteritis
por: Fernández-Fernández, Elisa, et al.
Publicado: (2022)

Genetic Predispositions of Glucocorticoid Resistance and Therapeutic Outcomes in Polymyalgia Rheumatica and Giant Cell Arteritis
por: Smutny, Tomas, et al.
Publicado: (2019)

Optimal management of giant cell arteritis and polymyalgia rheumatica
por: Charlton, Rodger
Publicado: (2012)

Genetic epidemiology: Giant cell arteritis and polymyalgia rheumatica
por: Gonzalez-Gay, Miguel A
Publicado: (2001)

Giant Cell Arteritis and Polymyalgia Rheumatica: 2016 Update
por: Nesher, Gideon, et al.
Publicado: (2016)

Liver involvement in polymyalgia rheumatica and giant cell arteritis
por: Hysa, Elvis, et al.
Publicado: (2020)

Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?
por: Goodfellow, Nicola, et al.
Publicado: (2017)

Cardiovascular diseases and their associations with lipid parameters and endothelial dysfunction in giant cell arteritis
por: Jud, Philipp, et al.
Publicado: (2023)

Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis
por: Evans, Jobie, et al.
Publicado: (2016)

Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis
por: Adriawan, Ignatius Ryan, et al.
Publicado: (2022)

Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis
por: Matza, Mark A, et al.
Publicado: (2023)

Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task force
por: Sanchez-Alvarez, Catalina, et al.
Publicado: (2023)

Giant cell arteritis with polymyalgia rheumatica on FDG‐PET/CT
por: Baba, Akira, et al.
Publicado: (2017)

Familial aggregation of longevity in giant cell arteritis and polymyalgia rheumatica
por: Milchert, Marcin, et al.
Publicado: (2020)

Predictive Factors of Giant Cell Arteritis in Polymyalgia Rheumatica Patients
por: Ramon, André, et al.
Publicado: (2022)

PTPN22 R620W minor allele is a genetic risk factor for giant cell arteritis
por: Lester, Susan, et al.
Publicado: (2016)

Geo-epidemiology of temporal artery biopsy-positive giant cell arteritis in Australia and New Zealand: is there a seasonal influence?
por: De Smit, Elisabeth, et al.
Publicado: (2017)

Vascular ultrasound for the diagnosis of giant cell arteritis: a reliability and agreement study based on a standardised training programme
por: Chrysidis, Stavros, et al.
Publicado: (2020)

Cardiovascular drug treatment, statins and biopsy-confirmed giant cell arteritis: a population-based case–control study
por: Turkiewicz, Aleksandra, et al.
Publicado: (2020)

Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
por: Cid, Maria C, et al.
Publicado: (2022)

Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register
por: De Miguel, Eugenio, et al.
Publicado: (2022)

Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis
por: Monti, Sara, et al.
Publicado: (2019)

A qualitative study of patient perspectives related to glucocorticoid therapy in polymyalgia rheumatica and giant cell arteritis
por: Hoon, Elizabeth, et al.
Publicado: (2019)

External validation of the 2022 ACR/EULAR classification criteria in patients with suspected giant cell arteritis in a Dutch fast-track clinic
por: van Nieuwland, Marieke, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v0vcavlq4jdahdi7gkm3gp1m6c